 This single arm study will assess the safety and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to current non-biologic DMARDs. Patients will receive iv infusions of tocilizumab 8mgkg every 4 weeks for a total of 6 infusions, either as monotherapy or in combination with their current non-biologic DMARDs. 